Cybin announces grant of two additional patents in japan in support of its dmt program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the japan patent (“jp”) office has granted jp patents 2023-500532 and 2023-533436. the patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection.
CYBN Ratings Summary
CYBN Quant Ranking